New Treatment Challenges the Old Approach to Head & Neck Cancer
Reading Time: < 1 minute
INTERVIEW ON THE PRICE OF BUSINESS SHOW, MEDIA PARTNER OF THIS SITE.
Recently Kevin Price, Host of the nationally syndicated Price of Business Show, interviewed Geert R. Kersten.
On a recent Price of Business show, Host Kevin Price interviewed Geert R. Kersten, Director and Chief Executive Officer of Cel-Sci, Inc.
According to a statement, “Cel-Sci’s lead product, Multikine (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent being developed as a potential treatment for head and neck cancer. Multikine is comprised of a mixture of cytokines; it is not one cell or one protein; it is a combination of molecules and proteins (interleukins, interferons, chemokines, and colony-stimulating factors) derived from the stimulation in the culture of normal immune system cells.
Results from their landmark phase 3 trial showed that Multikine produced significant 14.1% 5-year survival benefit (62.7% Vs 48.6%) in patients receiving surgery plus radiotherapy. These data indicate significant overall survival (OS) benefit for patients who received the Multikine® treatment regimen followed by surgery and radiotherapy, but not for patients who had chemotherapy added to the same treatment. The group showing significant survival benefit (no chemotherapy) represents approximately 155,000 patients per year globally or about 40% of newly diagnosed advanced primary head and neck cancer.”
Learn more at www.cel-sci.com.
LISTEN TO THE INTERVIEW IN ITS ENTIRETY HERE:
The Price of Business is one of the longest-running shows of its kind in the country and is in markets coast to coast. The Host, Kevin Price, is a multi-award-winning author, broadcast journalist, and syndicated columnist. Learn more about the show and its digital partners at www.PriceofBusiness.com (scroll down to the bottom of the page).
